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INTRODUCTION
Estrogen receptor (ER) status of breast tumor (expressed as + or – status) is a well-accepted predictor of response to endocrine therapy. In addition, a down-stream marker of functional 
ER signaling (1), progesterone receptor (PR), is measured in breast cancer (BC) biopsies and 
surgical samples. Now, it is known that two receptors for estrogen exist: ERD and ERE, encoded 
by two different genes: ERD is encoded by gene located on chromosomal loci 6q25.1 (2), and 
the ERELVHQFRGHGE\JHQHORFDWHGRQORFLT7KHH[LVWHQFHRIQXPHURXVLVRIRUPV
splice variants of both ERD and ERE, suggests that complex regulation of estrogen action exists. 
The exact biological significance of isoforms and its splice variants of both receptors (ERD and 
ERE), is still unclear, but it seems that their existence may have regulatory role in the response 
to estrogen. Both genes, ERD and ERE, have complex “system” of multiple promoters and 
differential splicing in 5’-UTR region (4). Exon deletions or duplications are second mechanism 
that potentially generates changes in reading frame, and, accordingly, exchanged proteins (5,6). 
In addition, five ERE isoforms (designated as ERE1 - ERE5) originate by alternative usage of five 
8th codons (7,8). It has been shown that the expression of ERD increases during the process of 
cancerogenesis, but the expression of ERE seems to decreases. Estrogen receptor E is under 
intensive investigation and its role in BC appears to be of predictive value, too. It is reasonable 
to propose that ER status should now include both receptors, ERD and ERE.
In this study, we measure expression levels of mRNA of two ERE variants ERE1 and 
ERE¨ :H DOVR GHILQH WKH FXWRII YDOXHV IRU (5E1 and ERE¨ P51$ H[SUHVVLRQ LQ
systematic sample of invasive BC. In addition, we compared ERE status with ERD and PR 
status. For this purpose, we quantified the expression levels of mRNA of two isoforms of 
ERE gene in 60 samples of primary operable BC samples and in adjacent normal tissue 
by the real-time RT-PCR. This study was performed by using the sensitive and sequence 
specific assays based on TaqMan methodology. Relative levels of ERE1 and ERE¨YDULDQW
were measured by assays designed to detect these transcript at unique regions.
MATERIAL AND METHODS
Patients 
We analyzed 60 samples obtained after surgery from patients with primary breast tumors, 
hospitalized at the Institute of Oncology and Radiology of Serbia in Belgrade. The study had 
received Institutional Review Board approval according to the National Health Regulation. 
Adjacent normal tissues are obtained after total mastectomy. Tissue was stored at liquid 
nitrogen until RNA and protein isolation. The patients all met the following criteria: primary 
operable unilateral invasive BC, without previous treatment. 
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ABSTRACT
Background: Estrogen and progesterone receptor (ER/PR) status is an accepted predictive marker 
in breast cancer. It is well known that breast tumors, which are ER(+) are more likely to respond to 
endocrine therapy. However, certain percentage of ER(+)/PR(+) tumors do not respond to endocrine 
therapy. Identification of the second estrogen receptor, named estrogen receptor beta (ERB), as well 
as the existence of numerous isoforms/splice variants of both ERA and ERB, suggests that complex 
regulation of estrogen action exists. In this study, we analyze does the expression of two ERB isoforms 
correlates with ERA/PR status.
Methods: Sixty samples of primary operable breast carcinomas were analyzed for ERA and PR protein 
levels and for mRNA expression of two ERB isoforms (ERB1 and ERB¨(5A and PR proteins were 
measured by classical biochemical techniques, and ERB mRNAs were measured by real-time RT-PCR. 
Results: Tumors are divided in three groups according to relative level of mRNA for ERB1 and ERB¨
We found that there is no correlation of ERB1 mRNA expression with ERA and PR protein levels. We 
confirmed the existence of inverse correlation of ERB¨ZLWK35DQGRI(5B¨ZLWK(5A in the group of 
postmenopausal patients. In the subsets of tumors defined by ERA/PR status, we found that percentage 
of tumors, which concomitantly expressed high levels of both transcripts, are parallel with those that do 
not response to tamoxifen treatment.
Conclusion: Inverse correlation of ERA with ERB¨DQG35ZLWK(5B¨LVRIRUPVXJJHVWVWKDW(5B¨
may have inhibitory effect on ERA activity in postmenopausal patients. In addition, we point out that 
determination of expression profiles of ERA and ERB isoforms in the defined groups of patient are nec-
essary for elucidating its involvement in endocrine resistance.
KEY WORDS: Breast Neoplasms; Receptors, Estrogen; Receptors, Progesterone; Antineoplastic Agents, 
Hormonal; Reverse Transcriptase Polymerase Chain Reaction
Arch Oncol 2006;14(3-4):106-9.
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ERB isoforms in breast cancer
Steroid receptor assay 
Steroid receptors, ERD and PR were measured by a five-point dextrane-coated charcoal 
assay in a cytosol fraction of frozen tumor tissue as previously described (9). 
RNA Isolation and cDNA synthesis 
The approximately 50–100 mg of tissue frozen in liquid nitrogen was pulverized in cold 
mortar vessel and extraction of total RNA was performed with acid-phenol guanidine 
method (10). Quality of RNA preparation was verified on agarose gels stained with ethidium 
bromide. RNA was dissolved again and concentration was determined spectrophotometri-
cally. Total RNA (1µg) was reverse transcribed in 20µl reaction volume with Omniscript 
RT Kit (Qiagen, Hilden, Germany) using the 10µM random hexamer and 1µM oligodT(15) 
primer according to manufacturer conditions (reverse transcription was performed 60 min 
RQ&
Real-time PCR analysis 
All PCR reactions were performed using a 7000 Sequence Detection System (Applied 
Biosystems). PCR was carried out in 25 µl reaction volume containing the 1x TaqMan 
Universal PCR Master Mix (Applied Biosystems), 1x TaqMan Pre-Designed Gene Expression 
Assay specific for target transcript sequence and cDNA diluted with water (1:10). Relative 
quantity of target transcripts ERE1 or ERE¨LQHDFKVDPSOHZDVH[SUHVVHGDVDQ1IROGGLI-
ferences relative to calibrator, or 1x sample, according to equation: N = 2¨&WVDPSOH²¨&WFDOLEUDWRU.
¨&WYDOXHVRIVDPSOHVDQGFDOLEUDWRUZHUHGHWHUPLQHGE\VXEWUDFWLQJRIDYHUDJH&WYDOXHRI
target transcripts (ERE1 and ERE¨IURPWKHDYHUDJH&WYDOXHRIE-actin gene (endogenous 
control) (11). 
Statistical analysis 
Since levels of expression show non-Gaussian distribution, nonparametric tests (Spearman, 
Mann- Whitney and Chi square) were used for the analysis of correlation with clinical and 
histopathological parameters.
RESULTS
Relative quantities of ERE1 and ERE¨P51$ZHUHH[SUHVVHGDVQIROGGLIIHUHQFHLQUHOD-
tion to calibrator and normalized to the E actin as a reference gene. Distributions of RNA 
expression levels for both transcripts were the same as distribution of ERD and PR proteins 
and according to Kolmogorov-Smirnov test, values vary significantly from the pattern of a 
normal distribution.
Expression of ERB1 and ERB¨P51$LQQRUPDODQGPDOLJQDQW
breast tissue
Concerned with fact that there are no cut-off values for ERE expression of mRNA level, and 
WKDW¨&WPHWKRGRIUHODWLYHTXDQWLILFDWLRQLVDSSOLHGZHGHILQHGWKUHHOHYHOVRIH[SUHVVLRQ
In this study we classified the BC samples according to expression of ERE1 and ERE¨
mRNA as “low expressed” (Tu1), “medium expressed” (Tu2), and “high expressed” (Tu3). 
Samples with “high expression” (Tu3) of ERE1 were defined as those in which more than 
three fold differences (in respect to calibrator) were detected; “medium expression” (Tu2) 
were those between one to three fold differences, and “low expression” (Tu1) were those 
with less than one fold difference. In the same way, the expression level is defined for 
the ERE¨H[SUHVVLRQEXWIRUVOLJKWO\GLIIHUHQWH[SUHVVLRQUDQJH7XPRUHWKDQVL[IROG
difference; Tu2 between two and six fold difference, and Tu1 less than two fold difference. 
This classification and numbers of samples in each expression group were showed in Table 
1. Expression levels of ERE1 and ERE¨P51$ LQ WKHVH WKUHHJURXSVRIVDPSOHVZHUH
compared with expression level in healthy mammary tissue (N), Table 1. Samples in “high 
expression” group (Tu3) does not differ significantly from the expression level in healthy 
mammary tissue (Tu3 vs. N, Mann-Whitney for E1, p=0.315, Figure 1; Tu3 vs. ERE¨
Mann-Whitney for E¨S )LJXUH6DPSOHVLQ´PHGLXPH[SUHVVLRQµJURXS7X
and in “low expression” group (Tu1) significantly vary from the expression level in healthy 
mammary tissue. For ERE1 Tu2 group vs. N, p=0.023, and Tu1 group vs. N, p=0.001 
(Mann-Whitney), Figure 1. For ERE¨7XJURXSYV1S DQG7XYV1S 
(Mann-Whitney). Expression between ”low expression” and “medium expression” groups 
does not differ significantly neither for ERE1, nor for ERE¨
It is apparently that Tu3 tumors (those do not differ from expression level in normal tissue) 
could be considered as ”positive” for ERE expression, and Tu2 and Tu1 could be considered 
as ”negative” for ERE expression. 
Table 1. Expression of ERE1 and ERE¨P51$LQEUHDVWFDQFHUDQGLQKHDOWK\PDPPDU\WLVVXH
Number of samples Mean* Median* Range*
ERB1
Breast cancer tissue
(+) High expressed (T3) (34) 12,340 6,928 3,091-70,427
(-)
medium expressed (Tu2) (14) 2,060 2,035 1,124-2,966
low expressed (Tu1) (12) 0,523 0,581 0,000-1,000
Healthy mammary tissue (N) 50,208 23,154 0,989-205,372
ERB¨
Breast cancer tissue
(+) High expressed (Tu3) (26) 21,074 9,962 6,272-102,508
(-)
medium expressed (Tu2) (25) 3,584 3,203 2,132-5,831
low expressed (Tu) (9) 1,108 1,007 0,000-1,754
Healthy mammary tissue (N) 108,811 48,694 2,662-358,389
*All values are expressed in relative expression level (n-fold difference in respect to 
calibrator) and obtained from 100 ng of total RNA.
Figure 1. Three groups of breast cancers according to expression of ERE1 isoform mRNA (Tu1, Tu2 
and Tu3) compared with healthy mammary tissue (N)
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Figure 2. Three groups of breast cancers according to expression of ERE¨LVRIRUPP51$7X7X
and Tu3) compared with healthy mammary tissue (N)
Correlation of ERB1 and ERB¨P51$H[SUHVVLRQZLWKWKHVWDWXVRI
ERD and PR
We examined does the expression status of ERE1 and ERE¨P51$V FRUUHODWHV ZLWK
ERD35VWDWXV$FFRUGLQJWR(5DVWDWXVVDPSOHVZHUHSRVLWLYHIPROPJRIWRWDO
cytosol proteins) and 24 were ERD-negative. According to PR status, 20 samples were 
35SRVLWLYHIPROPJRIWRWDOF\WRVROSURWHLQVDQGZHUH35QHJDWLYH
Analysis of association between ERD and PR protein levels shows no correlation with 
expression of the wild type of estrogen receptor beta (ERE1).
We found correlation between ERE¨P51$ DQG 35 SURWHLQ LQ WKH VXEJURXS RI SRVW-
menopausal patients (ERE¨YV35&KL VTXDUH S 0RUHRYHU LQ WKLV JURXSRI
patients significant inverse correlation exist between ERE¨P51$DQG(5D (Spearman,
R=-0.335, p=0.04). There is no correlation between ERE¨P51$DQG(5D or PR in the 
group of premenopausal patients (results not shown). 
In order to examine does the ERE expression correlates with established percentage of endo-
crine unresponsive patients, we analyze expression of both ERE transcripts in groups defined 
by the ER ERD35VWDWXV:HIRXQGWKDWWKHSHUFHQWDJHRIWXPRUVZLWKFRQFRPLWDQWO\KLJK
H[SUHVVLRQ OHYHO RI ERWK WUDQVFULSWV LQ WKH JURXSV RI (5SRVLWLYH35SRVLWLYH (5SRVL-
WLYH35QHJDWLYHDQG(5QHJDWLYH35QHJDWLYHSDWLHQWVDUHDQG UHVSHFWLYHO\
Assignment of the tumors with high expression of ERE1 and ERE¨7XLQWKHDERYHPHQ-
tioned groups of patients are parallel to the percentage of endocrine unresponsive ones. 
DISCUSSION
Majority of available data about ERE expression in clinical samples come from the immuno-
histochemical studies. Quantification of ERE expression on RNA level is justified, since the 
ERE mRNA increases in parallel with the increase in protein level as showed by Cheng et al 
(12), indicating that regulation of ERE expression is on transcriptional level. 
In this study, we performed the specific and sensitive TaqMan pre-designed assay for qPCR to 
quantify mRNA of ERE1 (wt isoform) and ERE¨ZKLFKLVDVSOLFHYDULDQWZLWKRXWILIWKH[RQ
of ERE2 isoform. ERE¨P51$HQFRGHGWUXQFDWHGSURWHLQZLWKRXWOLJDQGELQGLQJGRPDLQ
In examined samples of BC we found that there are two groups, according to expression 
of ERE1 and ERE¨ i) those that are not different compared to normal mammary tissue 
(referred as ERE-positive or “high expressed” (Tu3)), Table 1, Figure 1 and 2.; ii) and those in 
which expression levels significantly varies from normal mammary tissue (referred as ERE-
negative or “medium expressed” (Tu2) and “low expressed” (Tu1)), Table 1, Figure 1 and 2.
We found no correlation between expression of ERE1 mRNA, measured by qRT-PCR and 
ERD measured by ligand binding assay. Other authors also report (in immunohistochemi-
cal studies) that there is no correlation between ERD and ERE expression on protein level 
(13,14). The absence of correlation of ERE1 expression with clinical and histopathological 
parameters (our unpublished results), indicate that its expression level could be an indepen-
dent predictive marker in BC, but its predictive value remains to be established. 
Interestingly, little is known about expression of ERE¨LQWKHFOLQLFDOVDPSOHV'HOHWLRQVRI
fifth exon results in frame shift in reading frame of protein, generating five alternative amino 
acids, and stop codon after them, which results in truncated protein without ligand bind-
ing domain. In cell transfection studies (16), it was shown that ERE¨WUXQFDWHGSURWHLQ
possesses dose dependent, inhibitory activity against and ERD in 293T cell line. A similar 
activity, also in eukaryotic cell culture system, has its counterpart, ERD¨YDULDQWDJDLQVW
the ERD on ERE reporter genes. 
Our finding of inverse correlation of ERE¨ZLWK35DQGZLWK(5D in postmenopausal patients 
are in concordance with in vitro study of Inoue and coworkers (16) and may reflect the inhibi-
tory activity of this truncated protein in vivo against transcriptional activity of ERD receptor. 
Inverse correlation of PR and ERE2 was also reported by Saji and coworkers (17). Their data, 
together with our result that ERE¨DUHLQLQYHUVHFRUUHODWLRQZLWK35in vivo suggest that high 
expression of some ERE isoforms may underlie the emergence of ERDSRVLWLYH35QHJDWLYH
cells. Inverse association between expression of ERE¨YDULDQWDQGOHYHOVRI35SURWHLQPD\
be the consequence of inhibition of estrogen-induced activity of ERD by hetero-dimerization 
with truncated protein encoded by E¨VSOLFHYDULDQWDVSURSRVHGE\,QRXH2XUILQGLQJ
that this inverse correlation comes from postmenopausal subset of patients, points out that this 
inhibitory activity might be detectable in vivo only when levels of circulating estrogen is low.
,QDGGLWLRQZHIRXQGWKDWLQWKHVXEVHWVRISDWLHQWVGHILQHGE\WKH(535VWDWXVSHUFHQWDJH
of concomitantly “highly expressed” ERE1 and ERE¨DUHSDUDOOHOWRWKHHVWDEOLVKHGSHU-
centages of endocrine unresponsive patients. Poola and coworkers (15) recently published 
similar results where they show that two isoforms of ERE receptor (E1 and E5) are highly 
expressed in ERD-negative tumors. Biochemical explanation for this occurrence is that in 
the absence of ERD the ERE can be mediator of estrogen signaling as suggested by Poola 
(15). Moreover, there are data that tamoxifen may have agonistic effect on ERE in HeLa 
cells and BC cell lines. At the same time, high level of ERE¨YDULDQW ZKLFKGLPHUL]HV
with ERD (16)) may suppress the ERD activity. Although it is widely documented that the 
decreased expression of ERE correlates with tumor emergence and progression, the role of 
this receptor in tamoxifen resistance remains unclear.
Our approach in defining of ERE mRNA positive and negative is based on comparison 
between normal and malignant tissue is justified, since we obtained results comparable 
with data obtained in immunohistochemical studies. This approach may be helpful in future 
studies dealing with clinical significance of ERE.
In conclusion, we point out the necessity for analyzing the complete isoform profiles of ERE,
ERD and PR in clinical samples, since it is possible that one pattern of isoforms expression 
may be a cause of tamoxifen resistance and the other might be a marker of sensitivity.
Note
This work was supported by the Serbian Ministry of Science and Environmental Protection 
(Grant 143010 and Grant 145018).
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